1/2

JC971 U.S. PTO 09/834229

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

The Accompanying Application:

Applicant

Suad Efendic

For

USE OF GLP-1 OR ANALOGS IN TREATMENT OF

MYOCARDIAL INFARCTION

Docket No.

X-10822A

INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents Washington, D.C. 20231 Sir:

As a means of complying with the duty of disclosure, As permitted by 37 C.F.R. §1.98(d), Applicant refers to parent application Serial No. 08/915,918, filed August 21, 1997 for copies of the listed references.

Since this Statement is being filed in accordance with 37 C.F.R. 1.97(b), Applicant submits that no additional fee is required.

Applicant requests consideration of this information.

Respectfully submitted,

Mark J. Stewart, Ph.D. Attorney for Applicant Registration No. 43,936

Phone: 317-276-0280

Eli Lilly and Company Patent Division/MJS Lilly Corporate Center Indianapolis, IN 46285

April 12, 2001